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ABSTRACT Gender-aﬃrming treatment of transgender people requires a multidisciplinary approach in which endocrinologists play a
crucial role. The aim of this paper is to review recent data on hormonal treatment of this population and its eﬀect on physical, psychological,
and mental health. The Endocrine Society guidelines for transgender women include estrogens in combination with androgen-lowering
medications. Feminizing treatment with estrogens and antiandrogens has desired physical changes, such as enhanced breast growth,
reduction of facial and body hair growth, and fat redistribution in a female pattern. Possible side eﬀects should be discussed with patients,
particularly those at risk for venous thromboembolism. The Endocrine Society guidelines for transgender men include testosterone therapy
for virilization with deepening of the voice, cessation of menses, and increases of muscle mass and facial and body hair. Owing to the lack of
evidence, treatment of gender nonbinary people should be individualized. Young people may receive pubertal suspension, consisting of
GnRH analogs, later followed by sex steroids. Options for fertility preservation should be discussed before any hormonal intervention.
Morbidity and cardiovascular risk with cross-sex hormones is unchanged among transgender men and unclear among transgender women.
Sex steroid–related malignancies can occur but are rare. Mental health problems such as depression and anxiety have been found to reduce
considerably following hormonal treatment. Future studies should aim to explore the long-term outcome of hormonal treatment in
transgender people and provide evidence as to the eﬀect of gender-aﬃrming treatment in the nonbinary population. (Endocrine Reviews
40: 97 – 117, 2019)
T he acceptance by society, reﬂected in the media,that gender identity may not always match the
assigned sex at birth has provided the option and
permission for individuals to question their gender
identity more freely. Consequently, in some coun-
tries, transgender health services have expanded and
developed so that gender-diverse people wanting
physical change are able to access gender-aﬃrming
medical interventions. Hormone treatment, pivotal
for those who wish to transition into their aﬃrmed
gender that diﬀers from their sex that is assigned at
birth, is ideally prescribed under the supervision of
endocrinologists. However, many endocrinologists
may feel uneasy and unskilled when working with the
transgender population because the ﬁeld of trans-
gender medicine is relatively new. This review aims to
summarize the endocrine treatment of transgender
people wishing to undergo gender-aﬃrmation ther-
apies. The review ﬁrst describes the terminology used
in the ﬁeld of transgender medicine, followed by a
critical review of the diagnostic criteria currently in
use, and it summarizes the mental health diﬃculties
that transgender people may present with and the
beneﬁts of gender-aﬃrming treatment on well-being.
Finally, the major focus of this paper is to provide a
critical review of the published literature on the
hormonal treatment and long-term monitoring for
transgender children and adults.
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Terminology
The term “gender nonconforming” is used to describe
individuals whose gender identity, role, or expression
diﬀers from what is normative for their assigned sex at
birth in a given culture and historical period ().
Transgender is used as an umbrella term to describe
individuals whose gender identity diﬀers from the
assigned sex at birth. Transgender males are people
assigned female at birth but who self-identify as male.
Transgender females are people assigned male at birth,
but who self-identify as female. When a person’s
identity matches the sex assigned at birth, the term
“cisgender” is used. The term “nonbinary” describes
people whose gender identity, role, or expression does
not conform to the binary understanding of gender
(male or female). This can be used as an umbrella term
to include people with no gender (agender), two
genders (bigender), multiple genders (pangender), or
with a ﬂuid gender (gender ﬂuid) (, ), among others.
Nonbinary people prefer for people to use the pro-
nouns of “they” and “them” when addressing them ().
Terminology changes all the time, and terms used
in the past may become outdated and can be perceived
as pejorative. For example, the term transsexual, which
has been used since  (), is largely now conﬁned to
the legal and medical literature. The th edition of the
International Classiﬁcation of Diseases and Related
Health Problems (ICD-) () still uses the term
“transsexualism” as a diagnostic term to describe in-
dividuals whose sex assigned at birth does not match
their gender identity and want gender-aﬃrming
treatment. This term is likely to change to “gender
incongruence” in the forthcoming th edition of the
ICD (ICD-) (). Other terms still used but con-
sidered outdated (although they can still be found in
the literature) are “FtM” (female to male) to describe
transgender men or “MtF” (male to female) to describe
transgender women.
Gender dysphoria refers to a profound distress or
discomfort caused by the discrepancy between a
person’s assigned sex at birth and gender identity ().
Not every transgender person suﬀers from gender
dysphoria, and the urgency for medical intervention
among transgender people may vary (). For some
people, social change may be enough without the
need for further physical intervention. For others,
owing to their personal circumstances, physical in-
tervention may not be opportune or appropriate.
Many, however, will access transgender health ser-
vices to obtain gender-aﬃrming treatment whether
in the form of hormone treatment and/or through
gender-aﬃrming surgery. Research in the ﬁeld of
transgender medicine has primarily focused on
transgender people accessing transgender health ser-
vices (). Owing to the requirement in certain countries
to provide funded health services only to those with a
medical diagnosis, terms describing the gender-related
suﬀering of transgender people have remained part of
current diagnostic criteria (, ). In this review, the
term transgender is used throughout to describe
individuals who seek access to medical treatment in
order for their bodies to become more congruent to
their identiﬁed gender. A summary of some of the
terms used in transgender health can be found in
Table .
Methodology
Eligibility criteria
Studies were selected only when participants were
described as transgender (whether self-identiﬁed or
diagnosed by health professionals) and they had
empirical data relating to the hormonal treatment in
ESSENTIAL POINTS
· Transgender people before gender-aﬃrming treatment present with higher levels of mental health problems, particularly
depression, anxiety, and self-harm, than do cisgender people
· Gender-aﬃrming treatment has been found to reduce mental health problems in transgender people· Long-term estrogen and androgen-lowering medications may be associated with increased risk of thromboembolism,
which can be mitigated by changing the formulation and route of estrogen therapy
· Testosterone treatment in transgender men is seen as safe regarding cardiovascular and oncological disease in the short-
term and mid-term, but long-term eﬀects need to be elucidated
· The endocrine treatment of adolescents with gender dysphoria consists of two phases, ﬁrst pubertal suppression followed
by the addition of hormones
· The few somatic data available in adolescents are favorable and hitherto support the fact that the proven psychological
beneﬁts of early medical intervention outweigh the potential medical risks
· In well-informed transgender people regrets of gender-conﬁrming treatment are very rare
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this population. Only studies in English published in
peer-reviewed journals and with . participants
were selected. This is a critical review with a focus on
recent and original data. This paper describes and
reviews the available literature since the last published
review study by one of the coauthors of the current
review ().
Information sources and search
An electronic literature search included the period
between January  and November  used
Medline/PubMed, PsycINFO, and Embase. Addi-
tionally, reference sections of identiﬁed articles and
Google Scholar were examined for further rele-
vant publications. The search used keywords for
terms referring to transgender people (transsexualism,
transgender, gender dysphoria, gender identity disorder,
trans*) or hormonal treatment (cross-sex hormones,
testosterone, estrogen, blockers, GnRH agonist). Every
term used for transgender people was combined using
the “OR” and “AND” operators with every term used for
hormonal treatment. Articles of interest were those
that included the transgender population and had
empirical data relating to hormonal treatment within
this population. Articles describing the eﬀects of
treatment, side eﬀects, risk, and long-term outcome
were also collected and reviewed to help with the
discussion in this review. If information was only to be
retrieved from case reports, such as oncology, both the
case reports and recent reviews on the speciﬁc topic
were examined. The results of the present review
are presented by describing the treatment in adults
Table 1. Terminology Used in Transgender Health
Terms and Deﬁnitions
Cisgender: A person whose identity matches the sex assigned at birth.
Gender-aﬃrming treatment: Physical treatment that some transgender people access in order for their bodies to be adapted to the
bodies of their experienced gender or gender identity by means of hormones and/or surgery.
Gender dysphoria: A profound distress or discomfort caused by the discrepancy between assigned sex at birth and gender identity.
This is the same term as the current diagnostic term of the DSM-5.
Gender expression: The external manifestations of someone’s gender, which can include name, pronouns, clothing, haircut, behavior,
voice, or body characteristics.
Gender identity disorder: Diagnostic term used in previous versions of the DSM. The term is still used for the child diagnosis in the
ICD-10, but the proposed name for ICD-11 is gender incongruence of childhood. Currently this term is not preferred given the
term “disorder.”
Gender identity/experienced gender: A person’s internal sense of gender. Unlike gender expression, gender identity is not
visible to others.
Gender incongruence: The proposed diagnostic term to be used in the new edition of the ICD-11. Not all individuals with gender
incongruence have gender dysphoria or seek gender-aﬃrming treatment.
Gender reassignment: Previously used term to describe what is known now as gender-aﬃrming treatment.
Gender role: The behaviors, attitudes, and personality traits that a society, in a historical period, designates as masculine or feminine.
Natal sex: The term “sex assigned at birth,” which is usually based on genital anatomy, is more appropriate.
Sex: Attributes that characterize biological maleness or femaleness. They can include the sex-determining genes, the sex
chromosomes, the H-Y antigen, the gonads, sex hormones, internal and external genitalia, and secondary sex characteristics.
Sexual orientation: An individual’s physical and emotional attraction to another person. Gender identity and sexual orientation are
not the same. Irrespective of their gender identity, transgender people may be attracted to women (gynephilic), attracted to men
(androphilic), or be bisexual, asexual, pansexual, and so forth.
Transgender (adj.): An umbrella term to describe individuals whose gender identity diﬀers from the sex assigned at birth based on
their sexual characteristics.
Transgender female: A person who self-identiﬁes as female, but whose sex was assigned male at birth.
Transgender male: A person whose sex was assigned female at birth (based on sexual characteristics) but self-identiﬁes as male.
Transition: The process during which transgender people change their physical, social, and/or legal characteristics consistent with
their gender identity.
Transsexual (adj.): A diagnostic term used in the ICD-10. The term is currently used in some of the medical literature when
discussing diagnoses. The term transgender should now be used instead except when referring to the current ICD-10 diagnosis.
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(transgender women and men) ﬁrst, followed by the
treatment in adolescents.
Diagnosis
Currently the ICD- includes the diagnosis of
transsexualism as part of the diagnostic category of
“gender identity disorders” (F). It is expected that the
new edition of the ICD (ICD-) will change this term
and move it out of the mental health chapter. It is
likely that the new term to be used will be “gender
incongruence of adolescence and adulthood” (or
GIAA) (, , ).
The desire to de-pathologize being transgender and
the importance of securing access to health care has
been a dilemma in both the development of the
current edition of theDiagnostic and Statistical Manual
of Mental Disorders (DSM-) and the ICD-. The
American Psychiatric Association’s diagnosis in the
DSM- addresses the distress caused by the in-
congruence between assigned sex at birth and expe-
rienced gender as gender dysphoria. This diagnosis
aims to classify the symptoms (dysphoria) and not the
individual. For an individual to fulﬁll the diagnostic
criteria for gender dysphoria they need to present
with a marked incongruence between one’s experienced/
expressed gender and assigned gender, of at least
 months duration ().
If reaching a consensus to develop terms to classify
transgender adults has been complicated, creating
criteria for children has been even more complex. The
ICD- is proposing the diagnosis of gender in-
congruence in children () whereas the DSM- uses
the diagnosis of gender dysphoria in children.
Prevalence
More than  studies have sought to investigate
prevalence rates of transgender people. Although more
recently prevalence rates of transgender identities have
been reported using population studies, most of the
available literature has extrapolated prevalence rates
from people attending transgender health clinics ().
Some of the ﬁrst epidemiological studies, which
focused on individuals seeking services to undergo
gender-aﬃrming genital surgery (), found preva-
lence rates of . per , people. The ratio be-
tween male assigned at birth and female assigned at
birth was found to be  to  (). Other European
studies, based on people attending transgender health
services, provide diﬀerent prevalence rates over time:
. per , ( to ), . per , (
to ), and . per , ( to ) ().
Once again, rates of male assigned at birth transgender
people have been found to be higher than female
assigned at birth transgender people at a ratio of  to .
Studies looking at more recent periods (between 
and ) provide higher prevalence rates of . per
, with ratios between birth-assigned females
and males being more similar (. to ) ().
Studies have also examined the number of people
who have petitioned governmental agencies to change
their gender status legally. Those studies have de-
scribed prevalence rates ranging from . () to .
() per , people. A recent meta-analysis found
an overall prevalence for transsexualism (as this is the
diagnosis and term used in the published papers) of .
in , individuals: . for transgender women and
. for transgender men, with an increase in reported
prevalence during the last  years ().
However, not every transgender person wants and/
or seeks medical care to aﬃrm gender (). To identify
the overall prevalence of transgender people (in-
cluding those not accessing services) population
studies may be more representative of the transgender
community. Population-based studies have found a
considerably higher prevalence rate than those re-
ported in clinical studies. For example, a study asking a
sample of community participants in the United States
(, aged  to  years) as to whether they
considered themselves transgender found a prevalence
rate of .% (). Studies from the Netherlands and
Belgium described that .% () and .% () of
people assigned male at birth and .% () and .%
() of people assigned female at birth reported an
incongruent gender identity.
Most of the epidemiological studies have been
conducted in Western countries, particularly in Europe
and the United States. Societies that are more egalitarian
and open will facilitate the expression of gender di-
versity, and hence prevalence rates in those countries
may be reported higher than in more restrictive soci-
eties. Low prevalence rates in certain societies may need
to be regarded with caution, as they may reﬂect a
symptom of repression. A ban on gender identity ex-
pression for personal, cultural, or religious reasons
may manifest itself as distress and profound unhap-
piness and may lead to the development of mental
health problems ().
Mental Health in Transgender People and the
Eﬀect of Hormonal Treatment
Overall prevalence of mental health diagnoses
Studies investigating rates of mental health diagnoses
in the transgender population, once again, have fo-
cused on those attending transgender health services
(). Most of the studies have been cross-sectional and
report high rates of aﬀective disorders (%) () such
as depression () and adjustment disorders (), as
well as anxiety disorders (%) (, ). Rates of
nonsuicidal self-injuries have also been found to be
very high, particularly among young people (%) as
well as suicide attempts (–). The few studies that
compared their ﬁndings to the general cisgender
population (controlled by age and sex) found certain
mental health diagnoses, such as anxiety disorders, are
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threefold more prevalent among transgender people
compared with cisgender people ().
Diﬀerences in prevalence according to gender
There are some discrepancies as to whether mental
health diagnoses are more common among trans-
gender men or among transgender women. Some
studies have found that mental health diagnoses were
not related to assigned or identiﬁed gender (, ),
whereas other studies have demonstrated higher rates
of mood disorders (, ), anxiety disorders (),
adjustment disorders (), and substance abuse ()
among transgender women than among transgender
men. Most of those studies are biased by not con-
trolling for factors known to inﬂuence mental health
diagnoses, particularly hormone treatment. This means
that people have been recruited for studies indepen-
dently as to whether they are on hormone treatment or
not, although research has conﬁrmed that such treat-
ment reduces mental health problems. Interestingly,
more recent large controlled studies involving only
transgender people not on treatment have found that
anxiety disorders were more prevalent among trans-
gender men than among transgender women (). A
similar study also found levels of self-harm were also
higher among the same group ().
Predictors of mental health problems
Several factors have been found to predict mental
health issues among the transgender population at-
tending transgender health services, such as experi-
ences of victimization (or transphobic experiences),
low self-esteem (), and interpersonal problems (,
). Lack of hormone treatment of those wanting
physical change has been found to be the strongest
predictor of mental health diagnoses (, , ).
The role of hormone treatment in mental health
A number of longitudinal studies have explored the
role of hormonal treatment in mental health and
quality of life among transgender people wanting
gender-aﬃrmation treatment. These studies, which
have mainly been conducted in Europe [Sweden (),
Italy (), Belgium (), and Germany ()], have all
demonstrated that people’s mental health (levels of
depression and anxiety) signiﬁcantly improved fol-
lowing hormone treatment. Long-term follow-up
studies and studies involving large groups of people
are needed to evaluate whether these improvements
remain. Hence, hormone treatment of those wanting
physical change needs to be accessible, as this will
reduce morbidity and improve quality of life of
transgender people.
Posttreatment regrets
The literature on posttreatment regret is complex to
interpret. Overall satisfaction after gender-aﬃrming
treatment is high. A study from . years ago found
% of transgender women and % of transgender men
later regretted their decision to undergo hormonal
and/or surgical treatment (). There are many causes
of regret. Frequently dissatisfaction following gender-
aﬃrming surgery has been interpreted as regret re-
garding social and medical transition. To distinguish
those people who express dissatisfaction following
gender-aﬃrming treatment from those who wish to
detransition and return to their sex assigned at birth,
Pfa¨ﬄin () in  diﬀerentiated minor from major
regrets. In one of the largest gender clinics (Amster-
dam),  individuals received treatment between
 and . Ten of these people subsequently
indicated that they regretted their decision to have
undergone the treatment (nine transgender women
and one transgender man) (). The reason for those
regrets varied from identifying with the sex assigned at
birth and wanting detransition (n = ) (classiﬁed as
major regrets) to dissatisfaction of the outcome of
surgery or loss of support following gender-aﬃrming
treatment (n = ) (minor regrets). Upon review in
, the number of major and minor regrets in-
creased by  out of a total of  subjects. In  the
total number of subjects treated had risen to , but
there was no further increase in those expressing
regret. The fact that fewer people have been having
doubts about their treatment decisions over time may
reﬂect the much-improved understanding of gender
incongruence both by transgender people themselves
and by the medical profession, as well as much greater
acceptance of transgender people in society ().
Summary
Mental health diagnoses are common in the trans-
gender population, possibly owing to negative societal
values, but they do improve once gender-aﬃrming
treatment is initiated. This highlights the importance
of hormone treatment and access to adequate trans-
gender health care. Although state-funded health
services, which are primarily available in Europe, may
develop services where the needs of the transgender
population can be provided for, including assessment,
psychological support (when needed), hormonal
treatment, and gender-aﬃrming surgery, other health
care systems may not be so fortunate and transgender
people may ﬁnd themselves searching for professionals
who are able to conﬁdently prescribe and monitor
hormone treatment.
Results
Hormonal treatment in transgender women
Initial evaluation of transgender women
Transgender women seek hormone therapy to change
their physical appearance to better match their gen-
der identity and expression (, ). Furthermore,
“The medical professional
provides a more patient-
centered approach to care and
understands the needs of the
person rather than making
a diagnosis of the patient.”
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transgender women experience improved quality of
life and a decrease in gender dysphoria upon initiation
of hormone therapy (, ). In the United States,
Canada, and most of Europe, transgender women
must seek medical professionals for hormone therapy
because these medications are available only by pre-
scription, but there is a black market also particularly
for oral contraceptives. For non-Western countries,
hormone therapy is often self-prescribed without
supervision by a medical professional. Available evi-
dence from the United States and Europe suggests that
hormone therapy initiated and monitored under the
supervision of a medical professional is associated with
very low rates of adverse events (, ).
The Endocrine Society guidelines recommend
that a medical professional conﬁrm the diagnosis
of gender dysphoria and/or gender incongruence in
transgender women prior to the initiation of hormone
therapy. Medical professionals should document that
the gender dysphoria has been persistent and that the
individual is able to make an informed decision and
consent for treatment (). However, there are no
validated psychological tests or imaging studies that
have been clinically useful to diagnose gender dys-
phoria (), which is likely because people with gender
nonconforming expression and behaviors represent a
very large and heterogeneous population. There is
no demonstrable biological substrate for gender in-
congruence. In this regard, medical professionals have
been moving toward a more gender-aﬃrmative model
whereby the medical professional provides a more
patient-centered approach to care and understands the
needs of the person rather than making a diagnosis of
the patient (, ).
Screening for conditions prior to initiation of
hormone therapy
Medical professionals should evaluate transgender
women for conditions that can be exacerbated by
hormone therapy. Patients with a history of throm-
boembolic diseases such as deep vein thrombosis and
pulmonary embolism should undergo evaluation and
treatment prior to the initiation of hormone therapy
(). Additionally, risk factors that can increase the risk
of thromboembolic conditions should be modiﬁed
such as smoking, obesity, and sedentary lifestyle. In
patients with modiﬁable risk factors such as known
thrombophilia, past history of thrombosis, or a strong
family history of thromboembolism, treatment with
transdermal estrogen and/or concomitant treatment
with anticoagulation therapy may need to be con-
sidered, although there are limited data to guide
treatment decisions (, ). Other diseases such as
hormone-sensitive cancers, coronary artery disease,
cerebrovascular disease, hyperprolactinemia, hyper-
triglyceridemia, and cholelithiasis should be evaluated
prior to the initiation of estrogen therapy, as these
conditions can be exacerbated by estrogen.
Modalities of hormonal therapy in
transgender women
There are two main classes of medications used in
transgender women: () estrogen therapies and ()
androgen-lowering hormone therapies.
Estrogen therapies. The synthetic estrogen
ethinyl estradiol was a widely used estrogen in Europe
prior to . However, given recent safety concerns
about its prothrombotic potential and its potential role
in cardiovascular disease, most clinics have now
switched to oral, cutaneous, or IM estradiol (). A few
commonly used estrogen regimens in transgender
women have been reported [see appendix B of Ref.
()]; however, there are very few head-to-head studies
comparing the eﬃcacy and safety of estrogen regi-
mens. In a large multinational cohort study (titled
European Network for the Investigation of Gender
Incongruence) of four European countries (Belgium,
Netherlands, Italy, and Norway), . transgender
women were prescribed oral estradiol valerate at  mg
daily or estradiol valerate at mg IM every  weeks or
an estradiol patch ( mg daily), each with cyprot-
erone acetate (CPA) at  mg daily (). In the short
term (, years), these regimens are associated with
mild elevations of prolactin () and improvements in
bone mineral density (BMD) after  year of therapy
(). No short-term or long-term adverse events have
been published from this cohort using this hormone
regimen.
In a German cohort, transgender women were
treated with a regimen of estradiol valerate at  mg
IM every  days. The authors also reported short-
term gains in bone density after  months of therapy
along with higher body mass index (BMI) with an
increase of fat mass and decrease of lean body mass
().
In the United Kingdom, transgender women were
previously prescribed ethinyl estradiol or conju-
gated equine estrogen, but they are now changed to
oral estradiol at a dose of ~ mg daily (). In a
retrospective review of transgender women in the
United Kingdom, transgender women prescribed oral
conjugated equine estrogens had increased risk of
thromboembolism compared with transgender
women taking oral estradiol valerate or ethinyl es-
tradiol. In this cohort, .% of transgender women
on oral conjugated equine estrogen experienced a
thromboembolic event compared with ,% in
transgender women on estradiol or ethinyl estradiol
(P = .).
In the United States, estrogen therapy can be
prescribed as oral tablets, IM injections, and trans-
cutaneous preparations (). Most commonly pub-
lished in the United States is the prescription of oral
estradiol at  to  mg daily (, ). Studies that
compare the long-term safety and eﬀectiveness among
the diﬀerent formulations of estrogen are lacking. The
Endocrine Society guidelines recommend that the
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doses of estradiol be titrated to serum estradiol levels
at ~ pg/mL ( pmol/L) ().
Androgen-lowering therapies. Transgender
women will often require the addition of a medication
to lower testosterone levels into the female range ().
In most European countries, the most commonly
prescribed androgen-lowering medication is oral CPA
 mg daily (, , ). Cyproterone acts primarily as
an androgen receptor blocker but also has some
progesterone-like activity (). However, given reports
of increased risk of meningiomas (–), association
with depression (), and increased risk of hyper-
prolactinemia () with CPA use, in the United
Kingdom, transgender women are now prescribed
GnRH agonists to lower testosterone concentrations
(). In contrast to the rest of Europe and the United
States, GnRH agonists are provided free of charge to
transgender women by the National Health Service in
the United Kingdom ().
Spironolactone is the most commonly prescribed
testosterone-lowering medication in the United States
(, ). Spironolactone is classically known as an
antagonist of the mineralocorticoid receptor and a
potassium sparing diuretic. It also has antiandrogen
properties by directly lowering testosterone synthesis
and testosterone action at the androgen receptor ().
One US cohort of ~ transgender women found
estrogen therapy in combination with oral spi-
ronolactone at  mg daily was eﬀective in lowering
serum testosterone levels to the cisgender female range
for serum testosterone after ~ year of therapy ().
Peripheral androgen receptor blockers such as
ﬂutamide or dutasteride have not been recommended
for use in transgender women because these agents do
not lower serum testosterone levels and there are
limited published studies in this population ().
Other second-line hormonal therapies. Proges-
terone: Progesterone therapies such as medroxyproges-
terone have been used as a second agent to lower
testosterone concentrations in transgender girls and
women (). Some transgender women may request
progesterone to enhance breast development; however,
there are no clinical studies to support a positive eﬀect of
progesterone on breast development (). Furthermore,
there are concerns regarding potential increased risk of
thromboembolism and stroke found in cisgender women
taking progesterone (, ). Therefore, progesterone
therapy is not a routinely used medication in transgender
women.
a-Reductase inhibitors: Some transgender women
may experience male pattern hair loss and may seek
treatments to arrest hair loss and/or restore hair. In
general, lowering serum testosterone levels into the
cisgender female range is often adequate to arrest hair
loss in most transgender women; however, there are still
some transgender women who experience hair loss
despite lowered serum testosterone levels. A few case
series in transgender women with androgenetic alopecia
have demonstrated ﬁnasteride therapy to be eﬀective to
improve hair loss without signiﬁcant side eﬀects (, ).
The routine use of a-reductase inhibitors has been
limited over previous concerns of long-term sexual
dysfunction and depression reported to be found in
cisgender men (, ).
Feminization in transgender women
Treatment with estrogen and testosterone-lowering
medications will induce feminine and reduce mas-
culine physical characteristics Fig.  (). The most
studied physical change in transgender women is the
development of breast tissue. An Italian cohort study
found increases in breast size were the only physical
feature that was signiﬁcantly associated with im-
provement in body uneasiness scores (). How-
ever, ,% of transgender women reach Tanner
breast stage  to  after months of hormone therapy
and thus often seek mammoplasty. Early studies in
transgender women indicated breast development
reached a maximum size by  years (). However, a
more recent study of  transgender women par-
ticipating in the European Network for the In-
vestigation of Gender Incongruence cohort found that
breast development reached a plateau within the ﬁrst
 months of therapy and half of the transgender
women had a AAA cup size or less (). Fisher et al.
() also found that testicular volume decreased by
~% after  months of transfeminine hormone
therapy.
Body composition. In a meta-analysis of studies
published prior to , transfeminine hormone ther-
apy was associated with increased body fat and a de-
crease in lean body mass in  transgender women
(). More recent studies from Europe have docu-
mented that BMI increases in transgender women
after transfeminine hormone therapy (, ). Klaver
et al. () also demonstrated increases in body weight in
 transgender women, and transfeminine hormone
therapy was associated with an increase in body fat,
speciﬁcally in the android, leg, and gynoid regions.
However, recent studies from the United States have
demonstrated that important changes in BMI in
transgender girls and women do not occur during a
short term (, months) (, ).
Voice. Transgender women will have an im-
proved self-perceived feminine quality in their voice
after the initiation of hormone therapy (). How-
ever, many transgender women still have diﬃculty
with their voice quality and are misperceived in the
wrong gender by others (). Transgender women
may undergo voice training exercises to improve
their voice quality (). Laryngeal surgical treatment
has been described as an option for transgender
women to improve voice quality; however, a meta-
analysis failed to demonstrate a signiﬁcant beneﬁt of
surgical techniques to improve the quality of the
voice ().
“All transgender women
should be aware of the
potential fertility preservation
options such as sperm
cryopreservation.”
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Skin and hair. Transgender women will also
experience reduction in facial hair after transfeminine
hormone therapy. Fisher et al. () reported that
Ferriman–Gallwey scores improved after  years of
transfeminine hormone therapy. Transfeminine hor-
mone therapy may arrest male pattern hair loss (). A
survey of transgender women reported interest in
having facial hair removal procedures; however, few
data on the eﬀectiveness of such procedures have been
published ().
Safety data speciﬁc to transgender women
Cardiovascular and thromboembolic safety.
There have been some concerns about long-term
eﬀects of transfeminine hormone therapy on cardio-
vascular outcomes. A single-center study of .
transgender women from Belgium reported increased
rates of myocardial infarction, venous thrombosis, and
cerebrovascular disease compared with cisgender men
and women (). A recently commissioned system-
atic review and meta-analysis of cardiovascular out-
comes in transgender individuals did not ﬁnd an
increased risk of myocardial infarction, stroke, or
venous thrombosis in transgender women owing to
lack of reported outcomes from  eligible studies ().
This systematic review also found that transfeminine
hormone therapy was associated with increased serum
triglyceride levels of .mg/dL (%CI, . to .) in
transgender women treated for . months with no
changes in serum low-density lipoprotein or high-
density lipoprotein. Thrombosis risk in transgender
women is likely increased given the known pro-
thrombotic actions of estrogen. However, under
medical supervision, the risks of transfeminine hor-
mone therapy appear to be safer than self-prescribed
transfeminine hormone therapy (). A large study
conducted in  transgender women treated with
transdermal estrogen in Austria found that only
 had a genetic mutation associated with venous
thrombosis ( with protein C deﬁciency and  with
activated protein C resistance) and none developed a
thrombotic event, suggesting that estrogens that avoid
the hepatic ﬁrst-pass eﬀect may have less pro-
thrombotic risk (). Furthermore, given the low
frequency of genetic mutations associated with
thrombosis ( out of ), the authors do not rec-
ommend routine screening for thrombophilia. There
have been reports of transgender women who developed
Figure 1. Eﬀects of
estrogen and antiandrogen
treatment in transgender
women. [Reproduced with
permission fromTangpricha
V, den Heijer M. Estrogen
and antiandrogen therapy
for transgender women.
Lancet Diabetes Endocrinol
2017;5:291–300. (41);
©2019 Illustration
Presentation ENDOCRINE
SOCIETY].
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a thrombotic event and were successfully treated with
anticoagulation therapy (, ). However, there are no
long-term studies to guide treatment of transgender
women following a thrombotic event.
Bone health. The fracture rate associated with
transfeminine hormone therapy is unknown. Estrogen
is critically important for preserving BMD in post-
menopausal women and in men who lack estrogen
action at the bone (e.g., mutations in the estrogen re-
ceptor or aromatase enzyme) (, ). A recent meta-
analysis of  transgender women found a signiﬁcant
increase in lumbar spine BMD but no changes in hip
BMD. The rates of fracture were found to be low, with
no fractures found in  transgender women after
 months in this review (). A recent multicenter
study of  transgender women in Europe treated with
transfeminine hormone therapy found a .% increase
in lumbar spine bone density and a .% and .%
increase in total hip and femoral neck bone density,
respectively, after  year of therapy ().
Transgender women have been found to have
lower BMD even prior to the start of hormone therapy
(). Van Caenegem et al. () found that % of
transgender women had T-scores at the lumbar spine
below2. and approximately one third had T-scores
between2 and2. at the lumbar spine or total hip.
The reasons why transgender women had lower bone
density than expected for age are not clear, but the
authors hypothesized decreased outdoor physical ac-
tivity as an explanation, as vitamin D status was found
to be low in % of the cohort.
Oncological data and mortality. The preva-
lence of hormone-sensitive cancers such as breast and
prostate cancer appears to be low among transgender
women. Initial studies from a cohort of .
transgender women reported no increase in breast
cancer incidence compared with the expected rate of
breast cancer in cisgender women (). A large cohort
of . transgender military veterans in the United
States reported only nine cases of breast cancer in
transgender veterans, two in transgender women, and
seven in transgender men (). All of the transgender
women presented with late-stage breast cancer that
proved to be fatal, whereas the transgender men before
or after breast ablation presented with earlier disease
(). One the largest studies examining cancer risk in
transgender women in the United States used data
from one large health care system (Kaiser Permanente:
Georgia and Northern and Southern California ().
Using an electronic database method to identify
transgender women in this cohort, they identiﬁed 
transgender women subjects. Based on ICD- codes,
the investigators found no increased risk of breast
cancer or any cancer when comparing transgender
women to matched cisgender women. However, there
was an increased risk of breast cancer and endocrine
gland cancers in transgender women compared with
matched cisgender men. Furthermore, there was a
decreased risk of prostate cancer compared with
matched cisgender men. Other studies have reported a
low risk of prostate cancer in transgender women. A
recent review of literature of prostate cancer in
transgender women only found  cases reported ().
Other considerations. Fertility: All transgen-
der women should be aware of the potential fertility
preservation options such as sperm cryopreservation.
Transgender women report that they are interested in
having their own biologic children but very few trans-
gender women use fertility preservation technologies (,
), possibly due to the lack of funding for fertility
preservation in many countries. Because sperm pro-
duction will decline after the initiation of hormone
therapy, the Endocrine Society guidelines recommend
that all transgender women discuss fertility options with
their health care team prior to the initiation of hormone
therapy ().
Monitoring of feminizing hormone therapy: Trans-
gender women who take hormone therapy under
medical supervision experience very low rates of
complications (, ). Transgender women should
maintain serum estradiol and testosterone concen-
trations within the expected physiologic female range
(). The Endocrine Society recommends hormone
measurements every  months in the ﬁrst year of
initiating hormone therapy until the hormone con-
centrations reach the desired concentrations. Once the
hormone dose is achieved, the hormone concentra-
tions of both testosterone and estrogen can be mea-
sured once yearly or when there is a dose change to
ensure that levels remain in the range expected for
cisgender females (). Transgender women taking
spironolactone should have measurement of potas-
sium and kidney function on a regular basis. Following
surgery, transgender women can have a ﬁnal mea-
surement of serum testosterone to conﬁrm that levels
in the male range are eliminated.
Measurement of prolactin levels during the course
of gender-aﬃrming hormone therapy has been sug-
gested by the Endocrine Society guidelines. However,
recent reports indicate that elevated prolactin levels
seem to occur in transgender women on CPA and not
on spironolactone. Defreyne et al. () demon-
strated that prolactin levels increased in transgender
women receiving cyproterone but decreased after
discontinuation. Furthermore, a recent study by Fung
et al. () demonstrated that transgender women
treated with cyproterone had signiﬁcantly higher
prolactin levels compared with those treated with
spironolactone ().
Hormonal treatment in transgender men
Initial evaluation of transgender men
During the ﬁrst outpatient consultation, the same
principles apply as described for transgender women
above.
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Screening for conditions prior to initiation of
hormone therapy
Transgender men must be informed of the possibil-
ities, consequences, limitations, and risks of testos-
terone treatment. Fertility preservation options are to
be discussed before starting a medical intervention.
Pregnancy is an absolute contraindication for testos-
terone therapy, and relative contraindications include
severe hypertension, sleep apnea, and polycythemia
(). Conditions that can be exacerbated by testos-
terone therapy are presence of erythrocytosis, baseline
high hematocrit levels (e.g., secondary to smoking or
chronic obstructive pulmonary disease), sleep apnea,
and congestive heart failure. Knowledge on the presence
of menstruation problems prior to initiation of tes-
tosterone treatment and on sexual practices will guide
the need for follow-up procedures such as pelvic ul-
trasounds and pap smears.
Modalities of hormonal treatment in
transgender men
Testosterone. The principal hormonal treat-
ment used to induce virilization is testosterone. Under
medical supervision, testosterone therapy is safe based
on short-term and longer-term safety studies (, ,
). Diﬀerent testosterone formulations may be
available depending on geographical location. Most
commonly prescribed are injectable testosterone esters
(). More recently, subcutaneous administration of
testosterone was shown to be eﬀective and preferred by
transgender men at a median dosage  mg weekly in
 transgender men (, ), conﬁrming an earlier
intervention study (). Long-acting testosterone
undecanoate is also being used for treatment of
transgender men (). However, in the United States,
the prescription of testosterone undecanoate is limited
owing to the potential risk of oil pulmonary embolus,
and both patient and provider must undergo Risk
Evaluation and Mitigation Strategy training to receive
this therapy. Other intervention studies [see appendix
A of Ref. ()] have also used topical androgen gel or
transdermal patches. The use of oral testosterone
(testosterone undecanoate), axillary solutions, patches,
nasal sprays, buccal tablets, or pellets is rarely reported
for treatment in transgender men. In one study the
eﬀects of three diﬀerent testosterone formulations
were evaluated at baseline and after  months of
treatment and no diﬀerences were found regarding
short-term safety, compliance, body composition,
metabolic parameters, and general life satisfaction
(). Androgen therapy will need to be continued
lifelong to maintain the achieved virilization and to
avoid symptoms of hypogonadism such as vasomotor
symptoms or osteoporosis.
Progestational agents. If menstrual bleeding
does not stop after initiation of testosterone, a pro-
gestational agent, such as oral lynestrenol at  to mg
daily or medroxyprogesterone at  to  mg, might be
considered. This occurs frequently with the use of
transdermal or oral testosterone undecanoate, which
are both associated with lower testosterone levels
compared with injectable testosterone. GnRH analogs
to halt menses are theoretically possible, but they are
rarely reported in adults given the costs of therapy. If
ovariectomy is performed, the progestational medi-
cation can be discontinued (–).
Virilization in transgender men
Treatment in transgender men is intended to induce
virilization. This includes cessation of menses, de-
velopment of male physical contours, a deepening of
the voice, clitoral growth, increased sexual desire, and
increased facial and body hair (Fig. ) (, , ).
Male pattern baldness may also occur. Changes in
body composition, with redistribution of body fat and
increased muscle mass and strength, have been de-
scribed extensively (, , ). The time period
before cessation of menses may vary from  to
 months after testosterone initiation, sometimes
requiring the addition of a progestational agent (,
). Mean clitoral length may reach . 6 . cm
after  years of testosterone therapy ()
It is important that transgender men understand
the possibilities but also the limitations of testosterone
treatment. Height and bone structure (broader hips)
and the larger degree of subcutaneous fat remain
largely unchanged when therapy is started after pu-
berty (). Most of the published guidelines have
been developed with the white transgender person in
mind, but ethnic diﬀerences may warrant tailoring of
standard doses (). Recommendations based on
clinical experience are in favor of continuing testos-
terone treatment of elderly transgender men ().
Body composition. Testosterone therapy will
enhance a more masculine musculature, body shape,
and body fat distribution. Testosterone therapy will
result in changes in body composition. A meta-
analysis of  studies examining body composition
changes in response to testosterone during  months
found body weight increased by . kg (. to .),
body fat decreased by . kg (2. to 2.), and lean
body mass increased by . kg (. to .) (). An-
other systematic review, focusing among other pa-
rameters on BMI, revealed an increase in BMI from
.% to .% (). Grip strength increased with %
in a study with  participants and -year parenteral
testosterone undecanoate treatment ().
Voice. Testosterone therapy at doses in the
physiological range for men will induce acoustic
changes occurring from eﬀects on the larynx ().
In a cross-sectional study of  transgender men,
acoustic voice variables and voice quality were similar
between the transgender men and cisgender controls.
However, % of the transgender men experienced
issues with pitch quality, needing voice therapy and
sometimes pitch-lowering surgery (). Transgender
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men (n = ) whose voices sounded more congruent
with their experienced gender reported greater well-
being than did those with less gender-congruent voices
(). There are very few prospective data on the voice
changes in transgender men upon testosterone
treatment. Seven transgender men on IM testosterone
esters all reached a cisgender male mean fundamental
frequency within  months of testosterone therapy. A
mean decrease of  Hz was measured (). In the
largest longitudinal study to date (n = , with 
having data for baseline and -months follow-up),
acoustic analysis of fundamental frequency of the
habitual voice showed a signiﬁcant decrease after
 months (2 Hz), up to  months (2 Hz), with
group data congruent with cisgender male reference
data. In % of participants additional voice therapy
was necessary. When using an adapted version of the
Transsexual Voice Questionnaire () for trans-
gender men looking at self-perception of voice pro-
spectively during IM testosterone undecanoate
therapy in  participants, improvements during the
ﬁrst  months were attributed to the hormonal in-
tervention ().
Skin and hair. Both androgens and estrogens
are known to aﬀect the pilosebaceous unit of the skin,
as in the sebocytes and hair follicle dermal papilla
androgen and estrogen receptors are expressed. In a
study of  transgender men, IM testosterone therapy
was associated with increases in the Ferriman–Gallwey
hirsutism scores (). After  months, facial and
abdominal hair had not yet reached diameters found
in cisgender males. An increase in acne on the face and
back was present in % and %, respectively, after
 months. Data on both the shorter-term and longer-
term dermatological eﬀects of IM testosterone
undecanoate were available from a prospective in-
tervention study in  hormone-naive transgender men,
combined with a cross-sectional part with  trans-
gender men with an average of  years on various
testosterone treatments (). The Ferriman–Gallwey
Figure 2. Eﬀects of
testosterone treatment
in transgender men.
[Reproduced with
permission from Irwig MS.
Testosterone therapy for
transgender men. Lancet
Diabetes Endocrinol 2017;5:
301–311. (110); ©2019
Illustration Presentation
ENDOCRINE SOCIETY].
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score (in cisgender women usually ,) increased in a
time-dependent manner from a median of . to  after
 year, whereas long-term testosterone treatment
resulted in a median score of . The presence and
severity of acne based on the Gradual Acne Grading
Scale increased during the ﬁrst year and peaked at
 months; facial acne was present in %, and back
acne was present in %. Long-term data from this
study showed that % of transgender men had no to
mild acne. In a study with  transgender men, %
developed troublesome acne when treated with tes-
tosterone undecanoate for  years ().
In a retrospective, observational study,  trans-
gender men treated with testosterone esters or tes-
tosterone undecanoate self-assessed the degree of male
pattern baldness using a ﬁve-point scale [i.e., type I (no
hair loss) to type V (complete hair loss)]. The authors
found that % of transgender men had male pattern
baldness types II to V. Thinning of hair was related to
the duration of androgen administration and present
in half of the transgender men after  years ().
Wierckx et al. () reported that % of partici-
pants developed androgenic alopecia based on the
Norwood–Hamilton classiﬁcation after  year of
treatment. Longer-term ( years on average) testos-
terone treatment was associated with % of mild
frontotemporal hair loss and % moderate to se-
vere androgenetic alopecia (). In  transgender
men with androgenetic alopecia, treatment with oral
ﬁnasteride at  mg daily for  months induced im-
provement with one grade on the Norwood–Hamilton
scale after a mean of . months since the start of
treatment ().
Safety data speciﬁed for transgender men
Cardiovascular safety. Adult cisgender men
have higher cardiovascular mortality rates than do
women, which has been attributed to diﬀerences in sex
hormone levels. However, the available cardiovascular
outcome data in transgender men show that testos-
terone treatment does not result in adverse cardio-
vascular outcomes (). Four diﬀerent recent review
papers (, , , ) summarized the eﬀects of
testosterone on surrogate risk factors of cardiovascular
disease. These reviews demonstrated that despite a
perceived negative impact on a number of risk factors,
including an increase in hematocrit, a decrease in high-
density lipoprotein cholesterol, an increase in tri-
glycerides, low-density lipoprotein cholesterol levels,
and inﬂammation parameters (), a small increase
in systolic blood pressure (, ), and a decrease in
adiponectin and leptin (), no signiﬁcant increase in
cardiovascular outcomes was found (). Furthermore,
there have been no elevated rates of cardiovascular
deaths when compared with cisgender men and
women at short and medium follow-up in the larger
studies [except for one study ()]. However, data on
cardiovascular outcomes in older (+ years of age)
transgender men are mostly lacking (). In a cross-
sectional study of  transgender men on testosterone
treatment of an average of  years, no subject had
experienced myocardial infarction, stroke, or deep
venous thrombosis (). In a similar case-control
study,  transgender men on testosterone therapy
for an average of . years showed a low cardiovascular
morbidity (). In a prospective study with 
transgender men who were treated with testosterone
esters every  weeks, there was an increased incidence
of previously absent metabolic syndrome after 
(.%) and  years (.%), especially in those with
psychiatric comorbidity (). Furthermore, most
studies in transgender men report no adverse impact
of testosterone treatment on fasting glucose or insulin
sensitivity (, , , ).
Many studies report an association between tes-
tosterone therapy and increased Hb (range, +.% to
.%) and hematocrit (range, +.%–.%) during
the ﬁrst year of treatment, which then plateaus after
the initial year of treatment (, ). Clinically
signiﬁcant erythrocytosis has been reported but is
likely very uncommon (). In such cases, practi-
tioners sometimes advise change of the testosterone
route of administration or reduction of dosage, despite
the absence of outcome data showing risk reduction of
thrombotic events. In one study, use of testosterone gel
showed smaller increases in Hb (+%) and hematocrit
(+%) compared with injectable testosterone ().
A prospective study of  transgender men
treated with parenteral testosterone undecanoate and
lynestrenol for ~ years found no cases of venous
thromboembolic disease despite ﬁve subjects who had
the activated protein C mutation. The authors con-
cluded that general screening for thrombophilic de-
fects is not recommended (). In a similar study, 
transgender men followed for ~ years found no
cases of venous thromboembolism ()
Importantly, note that most transgender men are
still relatively young, at an age when the risk of car-
diovascular events is low. Long-term data and data
from older transgender men are needed.
Bone health. Sex steroid hormones play im-
portant roles in bone growth and maintenance. Men
develop larger, longer, and stronger bones during
puberty, explained through the combination of sex
steroids and mechanical loading. Testosterone therapy
in transgender men preserves bone density with ad-
equate dosing due to aromatization of testosterone to
estradiol (). There are very limited data on the risk
of osteoporotic fractures in transgender men ().
Transgender men have similar BMD compared with
cisgender females prior to testosterone therapy (,
, ).
Following ovariectomy, testosterone substitution
therapy appears to prevent short-term (, years) (,
, , , , –) and long-term (+ years)
(–) bone loss due to estrogen deﬁciency.
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Transgender men had larger cortical bone size com-
pared with cisgender females in a cross-sectional
study (). An additional study conﬁrmed the
higher cortical thickness by histomorphometric bone
biopsy study () and higher areal BMD at cortical
sites (, ). This reﬂects the eﬀect of androgens on
the periosteal circumference of cortical bone. The
androgen-induced higher muscle mass also induces a
higher mechanical load on the bone, possibly stim-
ulating bone formation according to the mechanostat
theory (). Higher bone formation was observed in
transgender men on testosterone (, , , ),
and both muscle mass and strength were positively
associated with trabecular and cortical parameters and
bone size. Nearly all studies reported a maintained
areal BMD, which argues against bone loss ().
However, in transgender men who underwent ovari-
ectomy, bone loss has been described when they ir-
regularly used or stopped androgen therapy or when
dosage was inadequate (, , ).
Oncological data and mortality. Both prac-
titioners and transgender men express concern around
carcinogenicity of long-term hormonal therapy, al-
though these concerns are not supported by the
available data. Recently, the published cancer case
reports in transgender men were summarized ():
one vaginal, one cervical, seven breast, one endome-
trial, and three ovarian cancers have been described to
date. The association to risk factors such as smoking
and alcohol use, sexually transmitted infections, and
lack of adequate access to screening programs has to be
acknowledged and included in future research ().
In transgender men on testosterone treatment and not
undergoing surgical interventions, breast and cervical
cancer screening protocols are advised, but timing and
frequency of monitoring of female internal organs in
transgender men are a matter of debate.
The available data on cancer mortality are limited
and based on studies on four diﬀerent populations
(Belgium, Sweden, Netherlands, and United States).
Despite low statistical power, these reviews demon-
strate very few cancer events in the population of
transgender men (, , , , , , ). The
data on overall mortality in transgender men, spe-
ciﬁcally related to testosterone treatment, are scarce,
and the few available studies are underpowered (). A
study from the Dutch cohort with  transgender
men (), with a later follow-up on  () and 
transgender men (), reported mortality to be
similar to those of the general population. The lack of
cancer outcome data underlines the need for studies
of a large and inclusive sample size and long-term
follow-up from multiple specialized centers.
Other considerations. Fertility: There is a clear
need to discuss reproductive options with transgender
men before starting testosterone treatment ().
From a study based on a questionnaire, % of the
transgender men desired to have children and %
would have banked oocytes had this been possible
(). Genital reconstructive surgery results in an ir-
reversible loss of natural reproductive capacities,
whereas testosterone therapy has an important but
partially reversible impact on fertility. In theory,
embryo and oocyte cryopreservation as established
techniques, and ovarian tissue cryopreservation more
experimentally can be mentioned as examples of
fertility preservation options (). The necessary
hormonal stimulations with multiple endovaginal
ultrasound monitoring are likely to be perceived as
physically and emotionally diﬃcult, making oocyte
cryopreservation not the preferred fertility preserva-
tion technique in this group, and some wish
to postpone this toward the time of hysterectomy
and oophorectomy. A strong suppression of anti-
Mu¨llerian hormone has been described in  trans-
gender men treated with a GnRH agonist, combined
with testosterone gel and an aromatase inhibitor ().
Reassuringly, androgen treatment did not deplete
the primordial follicles in the ovarian cortex strips,
and a normal distribution of cortical follicles in the
ovaries remained intact in  transgender men
after . year of testosterone treatment (). How-
ever, the use of in vitro maturation without the use of
xenotransplantation is far from implementation in a
clinical setting (). Once a mature oocyte is ob-
tained, the use of partner sperm or donor sperm and a
recipient uterus upon thawing of the oocytes, or a
female partner or surrogate mother, will enable
conception.
Based on an online survey in  transgender
men who had been pregnant, of which  had used
testosterone, % reported resuming menstruation
within  months upon interrupting testosterone
treatment, whereas % experienced no menses before
pregnancy. Of note, exogenous testosterone is not an
adequate means of birth control. Testosterone has
teratogen eﬀects on the fetus; therefore, transgender
men should avoid pregnancy while on testosterone
therapy. This is included in preconception counseling
that addresses stopping testosterone while trying to
conceive and during pregnancy, with the possibility of
increasing gender dysphoria during and after the
pregnancy. Postpartum, the options for breast feeding
and when to reinitiate testosterone have to be dis-
cussed ().
Monitoring of virilizing hormone therapy: Moni-
toring is advised three to four times in the ﬁrst year of
treatment and once or twice per year thereafter,
according to the Endocrine Society guidelines ().
Aiming at testosterone levels in the physiologic normal
male range and measuring hematocrit or Hb to avoid
erythrocytosis are the most important parameters.
Bone densitometry in transgender men should be
performed when risk factors (smoking, excessive al-
cohol use, family history of osteoporosis, history of
fracture, use of glucocorticoids, anorexia nervosa) for
“Treatment can generally start
when the adolescent is in
Tanner stages 2 to 3.”
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osteoporosis exist, and more speciﬁcally in those who
stop or temporarily interrupt hormone therapy after
gonadectomy. Screening for breast and cervical cancer
in transgender men who do not undergo surgical
interventions is advised ().
Hormonal treatment in adolescents
The endocrine treatment of transgender adolescents
consists of two phases: pubertal suspension or gonadal
suppression followed by the addition of hormones.
During the ﬁrst phase, pubertal development is halted
and adolescents can further explore their gender
identity and prepare for the next phase.
Gonadal suppression in adolescents
Gonadal suppression using GnRH analogs.
To achieve gonadal suppression generally, GnRHa
analogs (GnRHas) are used (). GnRHas have been
used since  in the treatment of central precocious
puberty (, ), and their beneﬁts are well estab-
lished and the use of GnRHa is regarded as both safe
and eﬀective, with no long-term adverse eﬀects ().
Treatment can generally start when the adolescent
is in Tanner stages  to . In clinical practice, trans-
gender boys usually can start when in Tanner breast
stage  and transgender girls when they have a tes-
ticular volume of  to  mL. Also, adolescents who
have already physically matured can use GnRHas to
inhibit unwanted pubertal development, such as breast
formation and menses in girls or further male phe-
notype development and erections in boys, until the
adolescent’s gender identity is more stable ().
The general safety and eﬃcacy of GnRHas have
been studied (, ). Anthropometry and body
development, hormonal status, and metabolic pa-
rameters were followed prospectively in  trans-
gender girls (median age at start, . years; Tanner
genital stage ) and  transgender boys (median age,
. years; Tanner breast stage ) during months of
GnRHa monotherapy. Puberty was adequately sup-
pressed with a decrease of testicular volume from .
(6.) mL to . (6.) mL in  transgender girls. In
transgender boys who initiated GnRHas early in
puberty at Tanner breast stage  and early menarche,
breast tissue fully regressed to stage  (n = ) and
menses ceased. Eﬀective gonadal suppression was also
reﬂected in a decrease in gonadotropin levels after a
period of  months to nearly undetectable levels and a
coinciding decrease in sex hormones. Testosterone
decreased from  ng/dL (. nmol/L) to, ng/dL
(. nmol/L) in transgender girls. In transgender boys,
estradiol decreased from a median of  pmol/L to 
pmol/L. As for anthropometry, height velocity de-
creased in both transgender boys and transgender girls
whereas BMI SD score calculated for sex assigned at
birth increased signiﬁcantly. Body composition and
the lean body mass percentage decreased and fat
percentage increased signiﬁcantly. Regarding safety
monitoring, glutamyl transferase, aspartate amino-
transferase, alanine aminotransferase, and creatinine
levels did not signiﬁcantly change from baseline to
 months of treatment, but alkaline phosphatase
decreased, most likely reﬂecting the decrease in growth
velocity ().
GnRHas are generally well tolerated with the ex-
ception of hot ﬂushes early in treatment ().
However, hypertension in transgender adolescents
under triptorelin treatment was reported in three
transgender boys in a cohort of  subjects. Hy-
pertension was reversible upon cessation of triptorelin,
but in one case increased intracranial pressure oc-
curred, requiring the temporary use of acetazolamide
(). GnRHa-induced hypertension is an uncommon
side eﬀect and has only been reported incidentally in
children (, ).
Gonadal suppression in adolescents using
other regimes. When resources cannot provide for
GnRHa alternative treatment, regimens should be
considered such as progestagens in transgender boys
or CPA in transgender girls (). Similar to trans-
gender women, endogenous androgen production can
be suppressed using antiandrogens such as CPA or
spironolactone in late pubertal girls. The eﬀects of
prolonged CPA monotherapy were studied retro-
spectively in  transgender girls who were in Tanner
genital stage . After  months of CPA at  mg
once daily, testosterone decreased from  ng/dL
(. nmol/L) to  ng/dL (. nmol/L) and
remained stable at  ng/dL (. nmol/L). LH and
FSH, however, were not suppressed at . IU/L and .
IU/L during this period. Prolactin increased from
. pmol/L to . pmol/L, but none developed
galactorrhea. Clinically more than half of the subjects
reported reduced shaving frequency and approxi-
mately one third had breast development (Tanner
breast stages  to ). There was no increase in BMI SD
scores. Fatigue was the only reported side eﬀect. As for
safety monitoring, only a transient increase of liver
enzymes was seen in % of the study subjects. The
levels remained under the threshold of three times the
upper limit and therefore treatment was not stopped.
Metabolic parameters such as lipid proﬁle and glucose
homeostasis were not negatively aﬀected ().
In postmenarche adolescent transgender boys an
alternative for GnRHas to stop or decrease menses
frequency may be the use of progestagens. A cohort of
 transgender boys (mean age of  years and in
Tanner breast stage ) was retrospectively studied
during .months of lynestrenol monotherapy. After
 months, metrorrhagia occurred in % but reduced
to % in the following  months. Subjects reported
headache (%) and hot ﬂushes (%). Serum LH
decreased from . IU/L to . IU/L, but levels of
FSH and estradiol remained unchanged. Weight
increased during the ﬁrst  months but returned
to baseline value after  months. Regarding safety
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monitoring, Hb and hematocrit increased but re-
mained in the normal male range. Liver enzymes, lipid
proﬁle, and glucose homeostasis were not negatively
aﬀected ().
The addition of gender-aﬃrming hormones to
GnRHa monotherapy
Hormone therapy in adolescents generally has two
treatment regimes. In the case when GnRHa treatment
is initiated in the early stages of pubertal development,
the “new” puberty is induced with a dosage scheme
that is also common in hypogonadal patients. Alter-
natively, when GnRHa treatment is initiated in late
puberty and thus the duration of the hypogonadal
state was limited, hormones can be given at a higher
initial dose and more rapidly increased until the ex-
pected adult dose. An additional advantage of GnRHa
treatment is that hormones do not have to be ad-
ministered in supraphysiological dosages, which would
otherwise be needed to suppress endogenous sex
steroid production ().
The timing of starting sex hormones in transgender
adolescents continues to be an issue of debate. The
recommended age of  years () is based on local
jurisdiction, and not on cognitive maturation or pu-
bertal development. In most countries at age  one is
considered to be legally adult and one can make
medical decisions. Indeed, when the ﬁrst studied co-
hort was started in the Netherlands the age of  was
chosen for this very reason. As a consequence there are
few data available on starting GnRHa at an earlier age.
The Endocrine Society guidelines make a recom-
mendation to allow hormone therapy to be initiated at
ages younger than  when the transgender child is
evaluated by a multispecialty team with expertise in
gender identity development in children. However, the
need for re-evaluating the recommended age for
starting GnRHa may shift in the future ().
Transgender girls. For a pubertal induction, it
is recommended to start b-estradiol at a dosage of
 mg/kg/d, followed by six monthly increments of
 mg/kg until a maintenance dosage of  mg is
reached. The second treatment regimen is more
suitable for transgender girls who initiated gender-
aﬃrming treatment when at least . years old.
After a period of gonadal suppression varying from 
to  months, estrogens can be given at a daily start
dosage of  mg and increased to  mg after  months
().
The eﬀects of the addition of b-estradiol were
studied prospectively in  transgender girls ().
Estrogen treatment was started at a median age of .
years after a median duration of . months of
GnRHa monotherapy. Breast development had started
within  months, and after  year median Tanner
breast stage was  progressing to  after  years (n = )
with a variability of all breast stages. With respect to
body shape, hip circumference increased and waist
circumference decreased. Although BMI increased,
BMI SD scores did not. When bone age was, years
at the start of estradiol, median height gain was . cm
after  years of estrogen therapy. Overall ﬁnal height
was . cm, corresponding to +. SD for Dutch
adult women. When the adult dose of mg of estradiol
daily was used during a median duration of  years, the
median serum estradiol was  pg/mL ( pmol/L)
[range, . to  pg/mL ( to  pmol/L)]. A change
in prolactin levels was not seen. Additionally, Hb,
hematocrit, HbAc, liver enzymes, and creatine remained
unchanged ().
Transgender boys. For pubertal induction the
use of testosterone ester injections is recommended.
The initial dose is  mg/m every  weeks IM and is
increased with  mg/m every  months. The
maintenance dosages vary from  mg per  weeks
for testosterone monoesters, such as testosterone
enanthate, to  mg per  to  weeks for testosterone
ester mixtures. For transgender boys who started
treatment in late puberty, testosterone can be started at
mg IM every  weeks, followed by the maintenance
dosage after  months (). It is advised to continue
GnRHa at least until maintenance dosage of testos-
terone is reached and preferred to continue until
gonadectomy. With androgens, virilization of the body
occurs, including lowering of the voice, more muscular
development, particularly in the upper body, facial and
body hair growth, and clitoral growth (, ).
Other considerations. Bone health in trans-
gender adolescents: During puberty, the bone mass
increases and peak bone mass is only achieved at the
age of  to  years (, ). Bone mass accrual is
regulated by genetic factors, gonadal hormones, and
environmental factors such as physical activity and
adequate supply of nutrients (calcium, vitamin D).
During the hypogonadal state induced by GnRHa
monotherapy, BMD is aﬀected (, ). In trans-
gender girls BMD of the lumbar spine remained stable
but z score decreased during . to  years of gonadal
suppression. In the femoral region, BMD and z score
decreased but not signiﬁcantly. In contrast, in trans-
gender boys the BMD of lumbar spine and femoral
region decreased together with the corresponding z
scores ().
When sex steroids are added, bone mass accrual
reassumes. In transgender girls, absolute BMD and z
scores in the lumbar spine but not the hip increased
(, ), but after  years of estrogen their z scores
were still below those of age- and sex assigned–
matched norms (). In transgender boys (, ),
the bone density and z scores of the lumbar spine and
the femoral region increased (n = ) after  years of
testosterone therapy but were still not at pretreatment
levels ().
When BMD development was assessed until young
adulthood, however, it was found that the loss in z
score was still partially present at the age of 
“GnRHa treatment in
adolescents is both clinically
and biochemically eﬀective in
suppressing the hypothalamic-
pituitary-gonadal axis and
appears to be well tolerated
and safe.”
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implying a possible delay in or loss of peak bone mass
(). To this date only one case report has been
published on long term BMD development and it was
shown that absolute BMD and z scores of a trans-
gender man, treated with GnRHa in his adolescence
was in the normal range at age . However pre-
treatment data were not provided ().
The addition of gender-aﬃrming hormones to
other methods of gonadal suppression: For trans-
gender girls, two retrospective studies reported on the
addition of estrogens to antiandrogen therapies in
transgender adolescents. In one study the subjects
received CPA (), and in the other study spi-
ronolactone () was used. The addition of estrogens
to CPA monotherapy in transgender girls resulted in
either the initiation or further progression of breast
development. Oral b-estradiol was started at . mg
daily and increased to . mg after  months. After
 months of estrogen therapy, .% reached Tanner
breast stage  and .% reached Tanner breast stage .
After  months, both testosterone and LH decreased
signiﬁcantly to  ng/dL (. pmol/L) and . IU/L,
respectively, and FSH demonstrated a declining trend
to . IU/L. The mean b-estradiol level was  pg/
mL (. pmol/L). The most common adverse event
reported by the transgender girls was fatigue but re-
solved in almost all. BMI SD scores remained stable. In
addition metabolic parameters, lipid proﬁle and glu-
cose homeostasis did not change ().
In a study of  transgender girls (mean age,  years;
range,  to  years) of whom  received spironolactone
(dosage,  to  mg daily), oral estrogen was added in
three routes: oral (dosage between  and  mg daily), IM
(dosage  to  mg monthly), or transdermal (dosage
. to . mg weekly). There were no changes re-
ported in BMI, metabolic parameters, lipid proﬁle, and
prolactin and there were no diﬀerences in the methods
of administration. Among the  subjects taking spi-
ronolactone, potassium levels did not change ().
For transgender boys, testosterone can be added to
progestagens as previously described () The clinical
eﬀects and eﬀects on metabolic parameters in ado-
lescent transgender boys have been investigated ret-
rospectively in two studies, one single-center study
(n = ) () and one multicenter study center (n =
) (); however, in the latter study, seven subjects
had received GnRHas prior to the testosterone ther-
apy. Only the single-center study reported on side
eﬀects, which were fatigue and acne. Clinically, there
was a weight gain as both BMI () and BMI SD scores
increased (). Although testosterone preparation
and dosing diﬀered, both studies reported an increase
in both Hb and hematocrit. With a testosterone ester
mixture on a biweekly frequency, values remained
within the normal male range (), whereas when
treated with testosterone ester on a weekly base,
hematocrit increased to supraphysiological levels
of .% in % of the cohort (two cases) with no
adverse events reported (). Alanine aminotransfer-
ase, aspartate aminotransferase, and creatinine in-
creased but remained in the normal range. Lipid
proﬁle was more unfavorable with an increase of
cholesterol and low-density lipoprotein and a decrease
of high-density lipoprotein. Glucose homeostasis pa-
rameters HbAc (, ) and insulin, glucose, or
homeostatic model assessment index () were not
aﬀected.
Final considerations. Knowledge regarding
the treatment of gender dysphoria and noncon-
forming has steadily advanced during the past  years
(). Although the psychological beneﬁts of gender-
aﬃrming treatment of young adolescents with gender
dysphoria using GnRHas have been established (,
), data on long-term health outcome are still sparse.
GnRHa treatment in adolescents is both clini-
cally and biochemically eﬀective in suppressing the
hypothalamic–pituitary–gonadal axis and appears to
be well tolerated and safe (). However, transgender
boys may be more susceptible to the development of
arterial hypertension (). Studies regarding treat-
ment with estrogen on pubertal development and
short-term safety demonstrate feminization of the
body without adverse events (). In transgender
boys, data on combined GnRHas and androgens is
lacking. Retrospective reports on BMD development
demonstrated a loss of z scores in transgender boys
and transgender girls during gonadal suppression,
followed by an increase after the addition of hor-
mones, but at the age of  years z scores were still
under pretreatment levels. Other long-term follow-
up data are not available. Also, the aforementioned
studies mainly describe a relatively older and mature
group, mid-teens and Tanner stage  and up, which
coincides with a relatively shorter duration of an in-
duced hypogonadal state. There are currently no
publications available focusing on treatment of the
young and less matured (Tanner stages  or ) ado-
lescents with gender dysphoria, and therefore the
eﬀects of prolonged gonadal suppression (i.e.,  to 
years) for the short term or long term are unknown.
There needs to be investigation when the initiation of
sex steroid hormones before the recommended age
of  may prevent the negative sequelae of hypo-
gonadism on the skeleton. Finally, when GnRHas are
not available, alternative methods to suppress puberty
can be used in the more sexually matured adolescent.
Short-term data on the uses of antiandrogens in
transgender girls and progestagens in transgender boys
demonstrated their eﬃcacy and safety (, ).
Key Conclusions and Recommendations for
Future Clinical Research
The current available research is based mostly on
cross-sectional studies, with limited longitudinal data.
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There is also a paucity of information on diverse
ethnic and socioeconomic populations and studies on
treatment outcome in adolescents. The current liter-
ature comes from mostly Western European and from
higher income countries, where many participants
undergo surgical procedures, and has at best in-
termediate duration follow-up. Limited data exist on
hormonal treatment in gender nonbinary persons. For
speciﬁc analyses such as outcome or mortality, no
single center has a suﬃciently large patient base to
study the population with statistical rigor.
An important barrier to better care is the diversity
of training and practice across providers. Health care
professionals continue to face challenges in providing
optimal care for the transgender population, also due
to a lack of education on the topic. The improvement
of formal transgender education in medical schools
and among health care providers in the broadest sense
is timely (). Professionals working in health services
need to understand that patient gender identity is
important and needs to be considered during any
consultation. Treating people with respect requires a
good understanding of people’s identity regarding
their gender. Transgender health care has to be in-
cluded in national and international conferences of all
involved specialties. We feel strongly about the fact
that involving the transgender community at all stages
of research is vital. This patient-centered research will
progressively lead toward more studies where trans-
gender community involvement is crucial in identi-
fying research priorities, research design, helping
recruitment, and dissemination of study results.
Patient-centered outcome priorities in endocrinology
are breast development in transgender women, time to
menstrual cessation in transgender men, dose-related
responses to hormonal interventions, and eﬀect on
sexual function and fertility, amongmany others ().
Transgender medicine research is ﬁnally moving
away from case reports and small series. Many eﬀorts
have gone into summarizing available data in nu-
merous recent systematic reviews, from which we have
to internalize the ﬁndings, avoid repeating the same
research, and take the investigations further. The
collection and reporting of original good quality data
through networks has to be higher on the agenda.
Innovative and patient-centered long-term research
with randomized controlled trials if possible, to ad-
vance of the safety and eﬃcacy of hormonal in-
terventions, is a priority. In doing so, clinicians and
academics must listen to the voices of transgender
people, recognizing and respecting the internal di-
versity within the transgender community.
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